Foundation Medicine, Inc., announced that it has completed the acquisition of Lexent Bio, Inc., a precision oncology company located in California, developing novel multiomics liquid biopsy platforms to advance cancer care. Foundation Medicine is a molecular insights company that offers a portfolio of comprehensive genomic profiling services to connect patients to cancer treatments and advanced precision medicine. This acquisition will accelerate Foundation Medicine’s research and development strategy and expand its existing liquid biopsy platforms to advance cancer care for patients.
